Eikon Therapeutics, Inc. (Nasdaq: EIKN) has selected a dose of 0.60 mg/m² for all patients randomized to receive EIK1001 in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE